Upgrade to SI Premium - Free Trial

UBS Reiterates Neutral Rating on Moderna (MRNA)

May 26, 2026 9:15 AM
UBS analyst Michael Yee reiterated a Neutral rating and $45.00 price target on Moderna (NASDAQ: MRNA).The analyst commented, "MRNA's Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments